# Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

> **NCT07347444** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 48 (estimated)

## Conditions studied

- Acral Melanoma
- Mucosal Melanoma

## Interventions

- **DRUG:** Iparomlimab and Tuvoraleimab injection+Bev+nab-PC

## Key facts

- **NCT ID:** NCT07347444
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347444, "Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07347444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*